- |||||||||| Perjeta (pertuzumab) / Roche
Clinical, Journal: Xeloda Oral, Trastuzumab, and Pertuzumab Combined Drug Therapy Reduced Cervical Lymphadenopathy and Dermal Involvement in Patient With Recurrent Breast Cancer: Case Report. (Pubmed Central) - Aug 6, 2021 Additionally, as reported in the literature, the use of xeloda plays a key role in restoring the skin health of patients with breast cancer presenting with skin metastasis. Our findings suggest that trastuzumab, pertuzumab, and xeloda combined therapy, following the schedule and posology handled in this study, can be a good treatment for recurrent HER2+ breast cancer with signs of supraclavicular lymphadenopathy and severe inflammatory BCA component with erythema and thickening of the skin.
- |||||||||| Herceptin (trastuzumab) / Roche
Clinical, Journal: Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. (Pubmed Central) - Jul 29, 2021 P=N/A TRA rates were similar across most standard regimens (docetaxel/carboplatin/trastuzumab +/- pertuzumab: 55.6%; docetaxel/cyclophosphamide +/- trastuzumab/pertuzumab: 41.8%; doxorubicin/cyclophosphamide/paclitaxel +/- trastuzumab/pertuzumab: 44.1%; but numerically lower with AC alone (25%) or paclitaxel/trastuzumab (11.1%)...Additionally, these data describe TRA associated with use of docetaxel/cyclophosphamide, which is increasingly being used in lieu of anthracycline-containing regimens. Collectively, these data can be used to inform use of fertility preservation strategies for women who need to undergo treatment as well as the potential need for ovarian suppression following modern chemotherapy for young women with estrogen-receptor-positive breast cancer.Clinical trial registration: www.clinicaltrials.gov, NCT01468246.
- |||||||||| Review, Journal: Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. (Pubmed Central) - Jul 28, 2021
The various agents differ greatly in their side-effect profiles and approved indications, from neoadjuvant and adjuvant use in early disease, to first- and later-line use in metastatic disease. This review discusses the current treatment recommendations for the use of anti-HER2 agents alone and in combination, examines the latest advances in HER2-targeted drugs and how they may be best applied in clinical practice, and provides guidance on optimal sequencing of the growing array of therapeutic options for HER2-positive breast cancer.
- |||||||||| Herceptin (trastuzumab) / Roche
Journal: Molecular Insights of Nickel Binding to Therapeutic Antibodies as a Possible New Antibody Superantigen. (Pubmed Central) - Jul 27, 2021 Comparisons with TCRs structures revealed similar interactions, demonstrating the possible underlying mechanism in selecting for Ni-binding IgEs and TCRs respectively. With the elucidation of the interaction, future therapeutic antibodies could also be sagaciously engineered to utilize such nickel binding for biotechnological purposes.
- |||||||||| Herceptin (trastuzumab) / Roche, Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial completion date: Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study (clinicaltrials.gov) - Jul 23, 2021 P2, N=462, Active, not recruiting, With the elucidation of the interaction, future therapeutic antibodies could also be sagaciously engineered to utilize such nickel binding for biotechnological purposes. Recruiting --> Active, not recruiting | Trial completion date: Feb 2032 --> May 2032
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
PK/PD data, Journal: Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics. (Pubmed Central) - Jul 23, 2021 Thus, the alternative 840 mg/420 mg Q4W and 840 mg Q6W pertuzumab dosing regimens are not recommended. Flexibility for IV PERJETA-based regimens is available with an alternative route of pertuzumab administration (subcutaneous vs intravenous).
- |||||||||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
[VIRTUAL] Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09 () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1710; P3 The primary endpoint is PFS by blinded independent central review. Secondary endpoints include PFS by investigator assessment, OS, ORR, DOR, PFS2, health-related quality of life (QOL), pharmacokinetics, immunogenicity, and safety.
- |||||||||| Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (clinicaltrials.gov) - Jul 14, 2021 P1, N=30, Recruiting, Given that many clinical trials exclude patients with brain metastases, clinical trials focused on patients with brain metastases should be pursued in the era of new HER2 therapies in MBC. Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2021 --> Aug 2022
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Perjeta (pertuzumab) / Roche
Journal: Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (Pubmed Central) - Jul 14, 2021 Additionally, the use of the antibody-drug conjugate trastuzumab-emtansine has led to a significant improvement in invasive disease-free survival for patients with residual disease following neoadjuvant therapy and has taught us the importance of using preoperative therapy to adapt adjuvant treatment...To stratify patient risks and optimize treatment selection, other biomarkers including intrinsic subtype, level of HER2, and tumor-infiltrating lymphocytes should be further evaluated. We discuss the latest evidence on the current approach of early-stage, HER2-positive breast cancer and present future perspectives on its management.
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, apitolisib (GDC-0980) / Roche
Clinical, Journal, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy. (Pubmed Central) - Jul 13, 2021 In the following MARIANNE trial also, a combination of T-DM1 plus pertuzumab delivered a non-inferior but yet not superior PFS compared to trastuzumab plus a taxane...Interestingly, both trastuzumab and T-DM1 induce PD-L1 expression in HER2 amplified BC cells. Our data provide evidence that an oncogenic mutation of PIK3CA and HER2-amplification may represent biomarkers to identify patients who may benefit most from the use of GDC-0980 and an opportunity to include immunotherapy in the combination of anti-HER2 therapy.
|